Dr. Alexander B. Olawaiye
Claim this profileUniversity of Pittsburgh Cancer Institute (UPCI)
Expert in Ovarian Cancer
Studies Fallopian Tube Cancer
21 reported clinical trials
45 drugs studied
Area of expertise
1Ovarian Cancer
Global LeaderStage IV
BRCA1 positive
Stage III
2Fallopian Tube Cancer
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Alexander B. Olawaiye is currently running
E7777 + Pembrolizumab
for Ovarian Cancer
Epithelial ovarian cancer (OC) is the most lethal gynecologic cancer: nearly 22,000 women are diagnosed with OC in the US annually and 63% are expected to die from their disease. The 5-year overall survival rate is unacceptably low at 20-30%, with \> 50% of patients experiencing recurrence of their disease. Recurrent, platinum-resistant OC is characterized by a low response to chemotherapy (\<10-15%) and poor prognosis, with overall survival estimated to be \<12 months. Thus, there is an urgent need to identify novel therapies to improve outcomes for patients with recurrent, platinum resistant OC. The primary focus in this trial is targeting tumor associated immunosuppressive T-regs with E7777 combined with PD-1 inhibitor, pembrolizumab. This trial will enroll patients with solid tumors in the dose escalation portion and specified cohorts in the dose expansion portion. In the Phase I portion, 18-30 patients will be enrolled. In the dose expansion portion, approximately 40 patients (20 in each cohort) will be enrolled. Given the relatively poor prognosis and limited treatment options for these patients, this population is considered appropriate for trials of novel therapeutic candidates.
Recruiting1 award Phase 1 & 216 criteria
ALX148 + Chemotherapy + Immunotherapy
for Ovarian Cancer
Immunotherapy with immune checkpoint inhibitors, including pembrolizumab, have emerged as a promising option in several solid cancers with durable effect and low toxicity profile. However, the benefit is limited to smaller subset of solid tumors. This trial involves the enhancement of current immune checkpoint-based immunotherapy with ALX148, an agent that inhibits CD47 (a trans-membrane protein that is highly expressed on the surface of many solid tumors as compared to normal cells).
Recruiting1 award Phase 214 criteria
More about Alexander B. Olawaiye
Clinical Trial Related3 years of experience running clinical trials · Led 21 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Alexander B. Olawaiye has experience with
- Pembrolizumab
- Olaparib
- Bevacizumab
- Paclitaxel
- Carboplatin
- Cisplatin
Breakdown of trials Alexander B. Olawaiye has run
Ovarian Cancer
Fallopian Tube Cancer
Endometrial Cancer
Ovarian Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alexander B. Olawaiye specialize in?
Alexander B. Olawaiye focuses on Ovarian Cancer and Fallopian Tube Cancer. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are BRCA1 positive.
Is Alexander B. Olawaiye currently recruiting for clinical trials?
Yes, Alexander B. Olawaiye is currently recruiting for 10 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Alexander B. Olawaiye has studied deeply?
Yes, Alexander B. Olawaiye has studied treatments such as Pembrolizumab, Olaparib, Bevacizumab.
What is the best way to schedule an appointment with Alexander B. Olawaiye?
Apply for one of the trials that Alexander B. Olawaiye is conducting.
What is the office address of Alexander B. Olawaiye?
The office of Alexander B. Olawaiye is located at: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania 15232 United States. This is the address for their practice at the University of Pittsburgh Cancer Institute (UPCI).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.